Reinhard Depping1, Moritz von Fallois1,2, Yosef Landesman3, Friederike Katharina Kosyna1. 1. Center for Structural and Cell Biology in Medicine, Institute of Physiology, Working Group Hypoxia, University of Lübeck, Lübeck D-23562, Germany. 2. Clinic for Radiotherapy, University Hospital Schleswig-Holstein, Lübeck D-23562, Germany. 3. Karyopharm Therapeutics, Newton, MA, USA.
Abstract
PURPOSE: The nucleocytoplasmic transport of macromolecules is critical for both cell physiology and pathophysiology. Exportin 1 (XPO1), the major nuclear export receptor, is involved in the cellular adaptation to reduced oxygen availability by controlling the nuclear activity of the hypoxia-inducible factors (HIFs). Recently, a specific inhibitor of XPO1, selinexor (KPT-330), has been identified that inhibits nuclear export of cargo proteins by binding to the XPO1 cargo-binding pocket. PATIENTS AND METHODS: We used different cancer cell lines from human tissues and evaluated the physiological activity of selinexor on the hypoxia response pathway in two-dimensional (2D) monolayer cell cultures in quantitative real-time (qRT)-PCR experiments and luciferase reporter gene assays. A three-dimensional (3D) tumor spheroid culture model of MCF-7 breast cancer cells was established to analyze the effect of selinexor on 3D tumor spheroid structure, formation and viability. RESULTS: Selinexor treatment reduces HIF-transcriptional activity and expression of the HIF-1 target gene solute carrier family 2 member 1 (SLC2A1). Moreover, 3D tumor spheroid structure, formation and viability are inhibited in response to selinexor-induced nuclear export inhibition. CONCLUSION: Here, we demonstrate the effect of specific XPO1-inhibition on the hypoxic response on the molecular level in 2D and 3D culture models of MCF-7 cells.
PURPOSE: The nucleocytoplasmic transport of macromolecules is critical for both cell physiology and pathophysiology. Exportin 1 (XPO1), the major nuclear export receptor, is involved in the cellular adaptation to reduced oxygen availability by controlling the nuclear activity of the hypoxia-inducible factors (HIFs). Recently, a specific inhibitor of XPO1, selinexor (KPT-330), has been identified that inhibits nuclear export of cargo proteins by binding to the XPO1 cargo-binding pocket. PATIENTS AND METHODS: We used different cancer cell lines from human tissues and evaluated the physiological activity of selinexor on the hypoxia response pathway in two-dimensional (2D) monolayer cell cultures in quantitative real-time (qRT)-PCR experiments and luciferase reporter gene assays. A three-dimensional (3D) tumor spheroid culture model of MCF-7 breast cancer cells was established to analyze the effect of selinexor on 3D tumor spheroid structure, formation and viability. RESULTS: Selinexor treatment reduces HIF-transcriptional activity and expression of the HIF-1 target gene solute carrier family 2 member 1 (SLC2A1). Moreover, 3D tumor spheroid structure, formation and viability are inhibited in response to selinexor-induced nuclear export inhibition. CONCLUSION: Here, we demonstrate the effect of specific XPO1-inhibition on the hypoxic response on the molecular level in 2D and 3D culture models of MCF-7 cells.
Authors: Terhi Jokilehto; Krista Rantanen; Marjaana Luukkaa; Pekka Heikkinen; Reidar Grenman; Heikki Minn; Pauliina Kronqvist; Panu M Jaakkola Journal: Clin Cancer Res Date: 2006-02-15 Impact factor: 12.531
Authors: Martin Wühr; Thomas Güttler; Leonid Peshkin; Graeme C McAlister; Matthew Sonnett; Keisuke Ishihara; Aaron C Groen; Marc Presler; Brian K Erickson; Timothy J Mitchison; Marc W Kirschner; Steven P Gygi Journal: Curr Biol Date: 2015-10-01 Impact factor: 10.834
Authors: Tyson V Sharp; Fernando Munoz; Dimitra Bourboulia; Nadege Presneau; Eva Darai; Hsei-Wei Wang; Mark Cannon; David N Butcher; Andrew G Nicholson; George Klein; Stephan Imreh; Chris Boshoff Journal: Proc Natl Acad Sci U S A Date: 2004-11-12 Impact factor: 11.205
Authors: Yun Pyo Kang; Jung-Ho Yoon; Nguyen Phuoc Long; Gi-Bang Koo; Hyun-Jin Noh; Seung-Jae Oh; Sae Bom Lee; Hyung Min Kim; Ji Yeon Hong; Won Jun Lee; Seul Ji Lee; Soon-Sun Hong; Sung Won Kwon; You-Sun Kim Journal: Front Oncol Date: 2019-03-21 Impact factor: 6.244